​

NanoProstin Group, LLC

Business Plan & Investment Summary

​

This document is a summary of the comprehensive business plan of NanoProstin Group.  It is intended for the sole use of potential officers, directors, management, and SEC-approved accredited investors.

 

Last Updated:  Jan. 14, 2022 

 

Notice:

The information contained in the Business Plan is confidential and is provided for the explicit purpose of evaluating the business of NanoProstin, (the “Company”) for investment.  The Business Plan and the information contained herein are not to be reproduced, revealed, shared, or communicated without the express written consent of the Company.

This confidential Business Plan was prepared by the Company for the express purpose of providing information on the Company to prospective investors. By acceptance of this Business Plan, the recipient agrees not to distribute it in whole or in part, at any time without the express written consent of the Company.  In addition, the recipient further agrees to keep confidential all of the information contained herein and also all information made available in connection with any further investigation of the Company, except information that is already in the public domain.  Upon request, the recipient agrees to promptly return the Business Plan and any other confidential information received from the Company.  In providing this Business Plan, the Company undertakes no obligation to provide the recipient with further Information.

 

While the information contained herein is believed to be true and accurate as at the date of its preparation, the Company makes no representation or warranty, express or implied, as to the accuracy or completeness of such information. The Company expressly disclaims any and all liability that may be based on such information, any errors therein, or omissions therefrom.

This document may contain Forward-Looking Statements, as these statements are commonly defined under the securities laws of various jurisdictions.  Actual results could differ materially from the results projected in such Forward-Looking Statements and such differences may be adverse.  The risks and uncertainties to which such results are subject are beyond the control of the Company or its management and are discussed in the Company’s report form 10-KSB as filed with the US Securities and Exchange Commission.

*All numbers are in US dollars.

​

Table of Contents:

1     Executive Summary   4

2     Operations    15

2.1  NanoProstin™    15

2.2  Methodology for Introducing a Drug to Market   27

2.3  Joint Venture Relationships    28

3     Industry Overview    32

3.1  The FDA Drug Approval Process    32

3.2  The Role of “Big Pharma”    32

3.3  The Cardiovascular Disease Treatment Market   33

3.4  Liposome Drug Delivery    33

4     Corporate Structure    34

4.1  Mission Statement    34

4.2  History of Angiomedx    34

4.3  Management Team    35

4.4  Board of Directors    37

4.5  Ownership Distribution    37

5     Financial Outlook    39

5.1  Exit Strategies    39

5.2  Survey of Existing Key Assets    40

6     Investment Summary    41

6.1  Capital Structure    41

6.2  Ownership Distribution   42

6.3  Use of Funds    42

Appendix A:  NanoProstin™ Phase II Clinical Trial    43

Appendix B:  NanoProstin™ PVD Treatment Study    46

Appendix C:  Intellectual Property    48

Appendix D:  Treatment of PAOD patients with Alprostadil - Pittau A.R., Montisci R., Brotzu G.   47

 

Executive Summary

NanoProstin Group, LLC (“NPLL”) is a biopharmaceutical technology limited partnership engaged in the development of pharmaceuticals, targeting endocrine, inflammatory, and cardiovascular diseases. The company maintains a portfolio of products in various stages of development, including Liprostin™; an intravenous medicine used for the treatment of Peripheral Artery Disease (PAD) (commonly called “hardening of the arteries”) and various vascular dysfunctions relating to diabetes, cardiovascular and heart disease. 

​

A question-and-answer dialog will provide more details and the history of NanoProstin (NPLL) once an approved SEC investor has requested more information.

​

Contact NanoProstin Group, LLC for more information and details.

​

​